Physician profile
Michael J Birrer
NPI 1164643714
$301,845.39
in general payments reported to CMS, 2019-2025
18 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126K · 2020: $60K · 2021: $43K · 2022: $22K · 2023: $20K · 2024: $17K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Food and Beverage: $2,337 · Travel and Lodging: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,594.07 |
| Food and Beverage | $2,337.45 |
| Travel and Lodging | $902.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $98,324.29 | 2019-2025 | Lynparza, Calquence, Tagrisso |
| Glaxosmithkline, LLC. | $43,250.01 | 2020-2025 | Jemperli, Zejula |
| Astrazeneca Uk Limited | $41,339.31 | 2019-2021 | |
| Eisai INC. | $30,703.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $25,978.74 | 2019-2025 | |
| Genentech USA, INC. | $17,070.91 | 2019 | |
| Tesaro, INC. | $16,014.07 | 2019 | |
| Emd Serono, INC. | $9,194.01 | 2019-2021 | |
| Clovis Oncology, INC. | $7,257.77 | 2019-2020 | |
| Aadi Bioscience, INC. | $6,205.88 | 2022-2025 | Fyarro |
| Emd Serono Research & Development Institute, INC. | $3,195.00 | 2023-2024 | |
| Blueprint Medicines Corporation | $1,680.00 | 2021 | |
| Exelixis INC. | $948.26 | 2023 | |
| Pfizer INC. | $565.16 | 2019-2024 | |
| Array Biopharma INC | $118.40 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Birrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.